Deal Details

Lexeo Completes $154 Million Follow-On Offering and Concurrent Private Placement

Healthcare

Lexeo follow-on offering and concurrent private placement

Summary

Lexeo Therapeutics, Inc. (“Lexeo”) (NASDAQ: LXEO) recently completed an underwritten public offering and concurrent private placement for gross proceeds of approximately $153.8 million. Lexeo offered 17,968,750 shares of its common stock, including the full exercise of the underwriters’ option to purchase additional common stock, in the public offering at an offering price of $8.00 per share. Concurrent with the public offering, Lexeo sold pre-funded warrants to purchase 1,250,015 shares of common stock to Balyasny Asset Management at a price of $8.00 per pre-funded warrant.

Baird acted as a lead manager on the public offering.

About

Lexeo is a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. Lexeo is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA) cardiomyopathy, LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy and others in devastating diseases with high unmet need. Lexeo is headquartered in New York, New York.

Healthcare

Lexeo follow-on offering and concurrent private placement